Huvepharma

Advance Properties through its 100% owned subsidiary Huvepharma International B.V., plays a significant role on the international market of human and veterinary healthcare products with a focus on livestock. 

A fast-growing global company, Huvepharma® focuses on developing, manufacturing and marketing  veterinary, feed additive and nutrition products for livestock and aquaculture. With more than half a century of expertise, Huvepharma® is the 10th largest healthcare provider in the world in this sector, offering high quality solutions for  livestock producers to improve the welfare and performance of their stock.

Huvepharma® believes in a unique operational model that combines an exclusive focus on key livestock growth areas with best-in-class reliable and tailored products made to the highest health and safety standards, all based on customer proximity and service models that foster trust. With its main production sites in the EU (Italy, France, Bulgaria) and the US, Huvepharma® is highly self sufficient with more than 95% of products produced at its own facilities. An investment of €230 million in capacity extension between 2018 and 2022 includes enlargement of  fermentation capacity to 10,000 m3 – one of the largest in Europe, and a state of the art vaccine plant. Huvepharma plans to realize €200 million green CAPEX by 2030 in the construction of solar parks, geothermal power plant and green hydrogen production plants.

Huvepharma® keeps top quality at all levels, employing highly qualified and experienced specialists in its R&D, production, regulatory affairs, sales and marketing structures.

Huvepharma® is committed to economic and environmental sustainability. The company has invested significantly in protecting the environment by installing modern incinerator plants and a number of exhaust air filtration installations at its facilities, as well as co-generation power plants generating energy for own use. Huvepharma® already operates olar plants with an installed capacity of 73MW and plans to increase it  to 300 MW by 2030. This is equivalent to electricity supply to 300.000 households. The company has started the process of decarbonizing its production facilities by relying on own energy production from renewable sources. All these actions are part of a longer-term vision to achieve climate neutrality. Huvepharma is Environment, Social and Governance (ESG) driven.

Huvepharma® has a strong vertically integrated business model which is unique in the animal health industry. This ensures reliability in the supply chain and control over the value chain by operating a client-demand driven approach which anticipates localized customer needs.

Huvepharma®’s global sales force consists of 550 long standing professionals in sales and marketing, as well as veterinarians and nutritionists – ensuring agility for the company and expertise and proximity to clients and customers across more than 100 countries around the world.

For additional information please visit www.huvepharma.com